Form 4: Processa Pharmaceuticals Director Yorke Acquires Shares

Justin W. Yorke, a Director at Processa Pharmaceuticals, Inc., acquired 203 shares of common stock through a time-based service award.

Summary

• Justin W. Yorke, a Director of Processa Pharmaceuticals, Inc. (PCSA), acquired 203 shares of common stock on June 26, 2026.
• This acquisition was a distribution of a time-based service award.
• Following this transaction, Yorke directly beneficially owns 353 shares of common stock.
• Additionally, Yorke indirectly beneficially owns 1,250 shares through Richland Fund, LLC and 496 shares through Directed Trust Company FBO Justin Yorke IRA.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it reports a routine stock award to a director rather than a significant purchase or sale that might indicate a strong market sentiment.

Positives

• Director Justin W. Yorke received a time-based service award, indicating continued incentive for leadership.
• The acquisition of 203 shares directly increases the director's stake in the company.

Future Outlook

No specific future outlook or guidance is provided in this filing, as it pertains to a change in beneficial ownership.

Industry Context

StockSavvy.ai notes that Form 4 filings, like this one from Processa Pharmaceuticals, are standard disclosures for insider transactions. These filings provide transparency into the holdings and transactions of company directors and officers, which can be a factor for investors monitoring insider activity.

Stakeholder Impact

• Shareholders: Increased transparency into director ownership, with a slight increase in direct beneficial ownership by a director.

Key Dates

Keywords

Processa Pharmaceuticals, PCSA, Form 4, Insider Trading, Director, Stock Award, Beneficial Ownership